Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010072740) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/072740 International Application No.: PCT/EP2009/067706
Publication Date: 01.07.2010 International Filing Date: 21.12.2009
IPC:
C07K 16/28 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
ASTRAZENECA AB [SE/SE]; IP Services SE-151 85 Södertälje, SE (AllExceptUS)
EBERLEIN, Catherine Anne [GB/GB]; GB (UsOnly)
FOLTZ, Ian [CA/CA]; CA (UsOnly)
KANG, Paul [CA/CA]; CA (UsOnly)
KENDREW, Jane [GB/GB]; GB (UsOnly)
ALFRED, Avril [CA/CA]; CA (UsOnly)
BARRY, Simon Thomas [GB/GB]; GB (UsOnly)
Inventors:
EBERLEIN, Catherine Anne; GB
FOLTZ, Ian; CA
KANG, Paul; CA
KENDREW, Jane; GB
ALFRED, Avril; CA
BARRY, Simon Thomas; GB
Agent:
BATES, Rosica Florence; MedImmune Limited Milstein Building Granta Park Cambridge Cambridgeshire CB21 6GH, GB
Priority Data:
60/140,33123.12.2008US
Title (EN) TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
(FR) AGENTS DE LIAISON CIBLÉS DIRIGÉS CONTRE Α5Β1 ET LEURS APPLICATIONS
Abstract:
(EN) The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
(FR) La présente invention concerne des agents de liaison ciblés contre α5β1 et leurs applications. Plus spécifiquement, la présente invention concerne des anticorps monoclonaux entièrement humains dirigés contre α5β1. Les agents de liaison ciblés selon l'invention peuvent être employés dans le traitement de pathologies associées à l'activité et/ou la surproduction de α5β1, ainsi qu'en tant qu'agents de diagnostic.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP2379595JP2012513194US20120114667CA2748158AU2009331528